Literature DB >> 31398011

Therapeutic Monosaccharides: Looking Back, Moving Forward.

Paulina Sosicka1, Bobby G Ng1, Hudson H Freeze1.   

Abstract

In this review, we focus on the metabolism of mammalian glycan-associated monosaccharides, where the vast majority of our current knowledge comes from research done during the 1960s and 1970s. Most monosaccharides enter the cell using distinct, often tissue specific transporters from the SLC2A family. If not catabolized, these monosaccharides can be activated to donor nucleotide sugars and used for glycan synthesis. Apart from exogenous and dietary sources, all monosaccharides and their associated nucleotide sugars can be synthesized de novo, using mostly glucose to produce all nine nucleotide sugars present in human cells. Today, monosaccharides are used as treatment options for a small number of rare genetic disorders and even some common conditions. Here, we cover therapeutic applications of these sugars and highlight biochemical gaps that must be revisited as we go forward.

Entities:  

Year:  2019        PMID: 31398011      PMCID: PMC7282196          DOI: 10.1021/acs.biochem.9b00565

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  176 in total

1.  Expression cloning of the Golgi CMP-sialic acid transporter.

Authors:  M Eckhardt; M Mühlenhoff; A Bethe; R Gerardy-Schahn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

2.  Human hepatic uridine diphosphate galactose pyrophosphorylase. Its characterization and activity during development.

Authors:  H D Abraham; R R Howell
Journal:  J Biol Chem       Date:  1969-02-25       Impact factor: 5.157

3.  Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans.

Authors:  M F McCarty
Journal:  Med Hypotheses       Date:  1997-03       Impact factor: 1.538

4.  Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan.

Authors:  M Brockington; D J Blake; P Prandini; S C Brown; S Torelli; M A Benson; C P Ponting; B Estournet; N B Romero; E Mercuri; T Voit; C A Sewry; P Guicheney; F Muntoni
Journal:  Am J Hum Genet       Date:  2001-10-08       Impact factor: 11.025

5.  Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome.

Authors:  Cory D Rillahan; Aristotelis Antonopoulos; Craig T Lefort; Roberto Sonon; Parastoo Azadi; Klaus Ley; Anne Dell; Stuart M Haslam; James C Paulson
Journal:  Nat Chem Biol       Date:  2012-06-10       Impact factor: 15.040

Review 6.  Oligosaccharides in human milk: structural, functional, and metabolic aspects.

Authors:  C Kunz; S Rudloff; W Baier; N Klein; S Strobel
Journal:  Annu Rev Nutr       Date:  2000       Impact factor: 11.848

7.  Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter.

Authors:  Ivan Martinez-Duncker; Thierry Dupré; Véronique Piller; Friedrich Piller; Jean-Jacques Candelier; Catherine Trichet; Gil Tchernia; Rafael Oriol; Rosella Mollicone
Journal:  Blood       Date:  2004-12-02       Impact factor: 22.113

Review 8.  Analysis and role of oligosaccharides in milk.

Authors:  L Renee Ruhaak; Carlito B Lebrilla
Journal:  BMB Rep       Date:  2012-08       Impact factor: 4.778

9.  Leukocyte Adhesion Deficiency Type II is a generalized defect of de novo GDP-fucose biosynthesis. Endothelial cell fucosylation is not required for neutrophil rolling on human nonlymphoid endothelium.

Authors:  A Karsan; C J Cornejo; R K Winn; B R Schwartz; W Way; N Lannir; R Gershoni-Baruch; A Etzioni; H D Ochs; J M Harlan
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

10.  Biallelic GALM pathogenic variants cause a novel type of galactosemia.

Authors:  Yoichi Wada; Atsuo Kikuchi; Natsuko Arai-Ichinoi; Osamu Sakamoto; Yusuke Takezawa; Shinya Iwasawa; Tetsuya Niihori; Hiromi Nyuzuki; Yoko Nakajima; Erika Ogawa; Mika Ishige; Hiroki Hirai; Hideo Sasai; Ryoji Fujiki; Matsuyuki Shirota; Ryo Funayama; Masayuki Yamamoto; Tetsuya Ito; Osamu Ohara; Keiko Nakayama; Yoko Aoki; Seizo Koshiba; Toshiyuki Fukao; Shigeo Kure
Journal:  Genet Med       Date:  2018-10-19       Impact factor: 8.822

View more
  4 in total

1.  Chemical Therapies for Congenital Disorders of Glycosylation.

Authors:  Paulina Sosicka; Bobby G Ng; Hudson H Freeze
Journal:  ACS Chem Biol       Date:  2021-11-17       Impact factor: 4.634

2.  Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.

Authors:  Zoé Durin; Marine Houdou; Willy Morelle; Lydia Barré; Aurore Layotte; Dominique Legrand; Mohamed Ouzzine; François Foulquier
Journal:  Front Cell Dev Biol       Date:  2022-05-26

3.  Association of galactose and insulin resistance in polycystic ovary syndrome: A case-control study.

Authors:  Zhijing Na; Hongyu Jiang; Yaxin Meng; Jiahui Song; Di Feng; Yuanyuan Fang; Bei Shi; Da Li
Journal:  EClinicalMedicine       Date:  2022-04-16

4.  The Effect of Acute Oral Galactose Administration on the Redox System of the Rat Small Intestine.

Authors:  Jan Homolak; Ana Babic Perhoc; Ana Knezovic; Jelena Osmanovic Barilar; Davor Virag; Mihovil Joja; Melita Salkovic-Petrisic
Journal:  Antioxidants (Basel)       Date:  2021-12-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.